Abstract | BACKGROUND: The extent of myocardial damage in patients with ST-segment elevation myocardial infarction ( STEMI) depends on both the time to reperfusion as well as injury induced by ischaemia-reperfusion resulting in a cascade of cellular and humoral reactions. As a consequence of ischaemia-reperfusion in the heart, the high-temperature requirement serine peptidase 2 (HtrA2) is translocated from the mitochondria to the cytosol, whereupon it induces protease activity-dependent apoptosis mediated via caspases. Myocardial damage induced by reperfusion cannot be monitored due to a current lack in specific biomarkers. We examined the serum level of HtrA2 as a potentially novel biomarker for mitochondrial-induced cardiomyocyte apoptosis. METHODS: After informed consent, peripheral blood was obtained from patients (n=19) with first-time acute anterior STEMI after percutaneous coronary intervention. Within this group, 10 of the patients received the mitochondria-targeting peptide elamipretide (phase 2a clinical study EMBRACE (NCT01572909)). Blood was also obtained from a control group of healthy donors (n=16). The serum level of HtrA2 was measured by an enzyme-linked immunosorbent assay (ELISA). In a murine model of myocardial ischaemia- reperfusion injury, HtrA2 was determined in plasma by ELISA after left anterior descending artery occlusion. RESULTS: HtrA2 median was significantly increased in patients with STEMI compared to healthy controls 392.4 (240.7-502.8) pg/mL vs. 1805.5 (981.3-2220.1) pg/mL (P⩽0.05). Elamipretide significantly reduced the HtrA2 median serum level after myocardial infarction 1805.5 (981.3-2220.1) pg/mL vs. 496.5 (379.4-703.8) pg/mL (P⩽0.05). Left anterior descending artery occlusion in mice significantly increased HtrA2 mean in plasma (117.4 fg/ml±SEM 28.1 vs. 525.2 fg/ml±SEM 96; P⩽0.05). CONCLUSION: Compared to healthy controls, we found significantly increased serum levels of HtrA2 in patients with STEMI. The result was validated in a murine model of myocardial ischaemia- reperfusion injury. In humans the increased serum level was significantly reduced by the mitochondria-targeting peptide elamipretide. In conclusion, HtrA2 is detectable in serum of patients with STEMI and might present a novel biomarker for mitochondrial-induced cardiomyocyte apoptosis. Consequently, HtrA2 may also show promise as a biomarker for the identification of ischaemia- reperfusion injury. However, this must be validated in a lager clinical trial.
|
Authors | Marcus Hortmann, Samuel Robinson, Moritz Mohr, Maximillian Mauler, Daniela Stallmann, Jochen Reinöhl, Daniel Duerschmied, Karlheinz Peter, James Carr, C Michael Gibson, Christoph Bode, Ingo Ahrens |
Journal | European heart journal. Acute cardiovascular care
(Eur Heart J Acute Cardiovasc Care)
Vol. 8
Issue 8
Pg. 695-702
(Dec 2019)
ISSN: 2048-8734 [Electronic] England |
PMID | 28534645
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Biomarkers
- Oligopeptides
- Placebos
- arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
- Serine Endopeptidases
- HTRA2 protein, human
- High-Temperature Requirement A Serine Peptidase 2
|
Topics |
- Aged
- Animals
- Apoptosis
(drug effects)
- Biomarkers
(blood)
- Female
- High-Temperature Requirement A Serine Peptidase 2
(blood, drug effects)
- Humans
- Male
- Mice
(blood)
- Middle Aged
- Mitochondria
(drug effects, metabolism)
- Myocardial Infarction
(blood)
- Myocardium
(pathology)
- Myocytes, Cardiac
(drug effects, metabolism, pathology)
- Oligopeptides
(administration & dosage, metabolism, pharmacology)
- Percutaneous Coronary Intervention
(methods)
- Placebos
(administration & dosage)
- Prospective Studies
- Reperfusion Injury
(blood, complications, veterinary)
- ST Elevation Myocardial Infarction
(blood, therapy)
- Serine Endopeptidases
(metabolism)
|